We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Enteroviruses Detected in Intestinal Specimens from Children with Advanced Ileocecal Crohn’s Disease

By LabMedica International staff writers
Posted on 09 Jul 2013
Enteroviruses have been detected in specimens taken from all the children in a small cohort with advanced ileocecal Crohn’s disease (ICD), while no enteroviruses were detected in specimens from normal children or from children with colon obstructions not related to Crohn's disease (CD).

Advanced ileocecal Crohn’s disease (ICD) is characterized by strictures, inflammation in the enteric nervous system (myenteric plexitis), and a high frequency of NOD2 (nucleotide-binding oligomerization domain-containing protein 2) mutations. More...
Homozygosity for a mutation in NOD2 increases the risk of the disease by a factor of 20 to 40. NOD2 encodes an intracellular protein that contains two caspase-recruitment domains, a nucleotide-binding domain, and 10 leucine-rich sequence repeats in the C-terminal region.

In addition to its relation to CD, recent findings have indicated a role for NOD2 and another CD susceptibility gene, ATG16L1, in the host response against single-stranded RNA (ssRNA) viruses. Since the role of viruses in CD was unknown, a multidisciplinary team of Swedish investigators hypothesized that human enterovirus species B (HEV-B), which are ssRNA viruses with dual tropism both for the intestinal epithelium and the nervous system, could play a role in ICD.

The research team, which included pediatricians, pathologists, virologists, molecular biologists, cell biologists and geneticists, worked with resections and biopsy specimens from a group comprising nine children with advanced, stricturing ICD, six patients with volvulus (abnormal twisting of the intestine causing obstruction), and 15 CD patients. The investigators used immunohistochemistry and in situ hybridization to demonstrate the presence of HEV-B and of the two HEV-B subspecies, Coxsackie B virus (CBV) and Echovirus.

Results showed that all patients with ICD had disease-associated polymorphisms in NOD2 or ATG16L1. Positive staining for HEV-B was detected both in the mucosa and in myenteric nerve ganglia in all ICD patients, but in none of the volvulus patients. Expression of the cellular receptor for CBV, CAR, was detected in nerve cell ganglia.

The common presence of HEV-B in the mucosa and enteric nervous system of the ICD patients in this small cohort was a novel finding that the investigators considered warranting further investigation to analyze whether HEV-B had a role in disease onset or progress. The presence of CAR in myenteric nerve cell ganglia provided a possible route of entry for CBV into the enteric nervous system.

Senior author Dr. Alkwin Wanders, associate professor of medicine at Uppsala University (Sweden) said, "This unique composition [of researchers], with complementary clinical and scientific expertise, has been extremely fruitful for our studies. Enterovirus could be thought to be stored in nerve cells in the intestine and to spread to different parts of the intestine via nerve fibers. This would explain both the fact that the disease is periodic and the fact that it often affects multiple segments of the intestines."

The study was published in the June 27, 2013, online edition of the journal Clinical and Translational Gastroenterology.

Related Links:
Uppsala University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.